Pirfenidone (Esbriet®)

Assessment Status Assessment Process Complete
Drug Pirfenidone
Brand Esbriet®
Indication For the treatment of mild to moderate idiopathic pulmonary fibrosis.
Assessment Process
Rapid review commissioned 15/12/2011
Rapid review completed 05/01/2012
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended
Full submission received from Applicant 26/11/2012
NCPE assessment completed 20/03/2013
NCPE assessment outcome Reimbursement not Recommended

Technical Summary

The NCPE believe that, at the submitted price, pirfenidone is not cost-effective for the treatment of patients with mild to moderate Idiopathic Pulmonary Fibrosis.

The HSE has approved reimbursement following confidential price negotiations March 2015.